secwatch.observer — SEC 8-K summary
======================================

Issuer:     Generation Bio Co. (—)
CIK:        0001733294
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001104659-25-121219
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA Royalty to acquire Generation Bio for $4.2913/share plus CVR tied to Moderna deal
--------------------------------------------------------------------------------

- Cash consideration of $4.2913 per share plus one non-transferable CVR per share; CVR payments from net cash >$29M, lease savings, Moderna milestones/royalties, and ctLNP platform licensing.
- Tender offer expected to close in February 2026; condition requires at least a majority of shares tendered; support agreements cover ~15% of outstanding shares.
- CVR holders receive up to 90% of Moderna collaboration proceeds (years 1-3) and up to 70% of platform licensing proceeds (years 1-2), declining over 10-year period.
- Generation Bio Board unanimously approved; termination fee of $840k payable by Generation Bio under certain circumstances.
- Acquisition provides XOMA Royalty with potential milestone and royalty payments from Generation Bio's existing Moderna collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733294/000110465925121219/0001104659-25-121219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733294/000110465925121219/gbio-20251215x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-121219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer